Precision BioSciences Receives Two Notices Of Allowance From USPTO For Patent Applications Relating To PBGENE-HBV Program

Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has received two Notices of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent applications relating to the Company's PBGENE-HBV program.

The first Notice of Allowance relates to U.S. Patent Application No. 19/347,136, titled "Engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome." The '136 application includes composition of matter claims that, when granted, will encompass the ARCUS nuclease utilized in PBGENE-HBV.

The second Notice of Allowance relates to U.S. Patent Application No. 19/273,982, titled "Polypeptide linkers for use in engineered meganucleases." The '982 application includes composition of matter claims that, when granted, will encompass any polypeptide—including the PBGENE-HBV ARCUS nuclease—that comprises a novel, shortened polypeptide linker developed by Precision. Future ARCUS nucleases incorporating this novel polypeptide linker will also be covered by the granted claims.

When issued, each patent arising from these applications is expected to have a standard expiration date in November 2044.